<DOC>
	<DOCNO>NCT00005921</DOCNO>
	<brief_summary>The purpose study see safe give L-743,872 men candidal esophagitis , AIDS-related yeast infection esophagus .</brief_summary>
	<brief_title>A Study Side Effects L-743,872 Men With Candidal Esophagitis</brief_title>
	<detailed_description>In open-label study , patient receive intravenous L-743,872 every 24 hour one three dose level 14 day . Post-study safety evaluation continue 4 week final dose . Pharmacokinetics safety measurement take throughout 6-week study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are 18 65yearold man candidal esophagitis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Candidiasis</keyword>
	<keyword>Esophageal Diseases</keyword>
	<keyword>MK 0991</keyword>
</DOC>